TiGenix specializes in stem cell therapies. Their latest showpiece is Cx601, a treatment for symptoms associated with Crohn’s disease. To bring their innovation to the clinic, they can now count on their new owner, Takeda.
The two companies are no strangers to each other. Today, Takeda already has a 4.2 percent share in TiGenix, and just last year, the firms signed an agreement to commercialize medicines based on Cx601 in the US. With the new deal, which is expected to take effect in spring 2018, Takeda confirms its belief in Flanders’ thriving biopharma ecosystem. Eduardo Bravo, CEO of TiGenix: “We trust that our stem cell expertise, combined with Takeda’s ambitious mindset and extensive resources, will accelerate the development of stem cell therapies worldwide.”